Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Delving into the topline data from the Phase 2/3 DEVOTE study of higher dose Spinraza (nusinersen) in patients with SMA

Ticker(s): BIIB

Who's the expert?

Institution: Duke University

Former Co-Director of Duke Children's Neuromuscular Program & Professor of Neurology and Pediatrics at Duke, recently made a career change and is now exclusively focused on clinical trials.
Treated hundreds of neuromuscular patients, including 150 DMD patients of all ages in 2023
Actively involved in clinical research and many trials with a focus on pedicatric neuromuscular diseases; PI on multiple DMD studies including an Exon 53 skipping specific study.

Interview Goal

This call will discuss the current treatment landscape and the potential of Spinraza (nusinersen) a prescription medicine used to treat SMA in pediatric and adult patients including the recent data from the Phase 2/3 DEVOTE study.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.